Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

Rhea-AI Summary

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced its plan to release third quarter 2022 financial results on November 10, 2022. The management will host a conference call at 4:30 p.m. ET to discuss the results, with live audio accessible via the company's investor relations website. Participants are required to register for dial-in details, enhancing security and streamlining access. Eton specializes in developing treatments for rare diseases and currently has three FDA-approved products, along with several candidates in late-stage development.

Positive

• Three FDA-approved products: ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution.
• Three late-stage pipeline candidates: dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, and ET-400.
• Royalties from three additional FDA-approved products and potential milestone payments.

Negative

• None.

DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).

Register* (Audio Only)         Click Here

In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.

The live webcast can be accessed on the investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

* Beginning this quarter, conference call participants should register to obtain their dial-in and passcode details. The new, streamlined process improves security and eliminates wait times when joining the call. Please be sure to register using a valid email address.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has three FDA approved products in ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution, and three late-stage pipeline candidates under development with dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, and ET-400. In addition, the Company receives royalties on three FDA-approved products and is entitled to receive milestone payments on other products.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals

FAQ

When will Eton Pharmaceuticals report its Q3 2022 financial results?

Eton Pharmaceuticals will report its Q3 2022 financial results on November 10, 2022.

What time is the conference call for Eton Pharmaceuticals Q3 results?

The conference call for Eton Pharmaceuticals' Q3 results is scheduled for 4:30 p.m. ET.

How can I access the Eton Pharmaceuticals Q3 earnings call?

You can access the Eton Pharmaceuticals Q3 earnings call via their investor relations website after registering for dial-in details.

What products are currently FDA-approved by Eton Pharmaceuticals?

Eton Pharmaceuticals has three FDA-approved products: ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution.

What are the late-stage pipeline candidates for Eton Pharmaceuticals?

Eton Pharmaceuticals has three late-stage pipeline candidates: dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, and ET-400.